Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation

Goldman Sachs initiated coverage of Viatris (WBAG:VTRS) on June 6, 2025, with a Neutral recommendation, while the average analyst one-year price target suggests a 28.60% upside from the latest closing price. Institutional ownership in Viatris has seen a slight decrease of 2.62% in the last three months, with 1,653 funds holding positions, reflecting a decrease of 1.90% from the previous quarter; however, the average portfolio weight dedicated to VTRS by these funds has increased by 22.74%.

Analysis

Goldman Sachs initiated coverage on Viatris (WBAG:VTRS) on June 6, 2025, with a Neutral recommendation, even as the average analyst one-year price target of €9.75/share, as of June 2, 2025, implies a substantial 28.60% upside from its latest closing price of €7.58. This target is supported by a forecast range of €7.14 to €12.16. Viatris is projected to achieve annual revenue of €15,330MM, a 6.98% year-over-year increase, and an annual non-GAAP EPS of €2.96. Institutional ownership presents a nuanced picture: the number of funds holding Viatris declined by 1.90% to 1,653, and total institutional shares decreased by 2.62% to 1,158,925K in the last quarter. However, the average portfolio weight dedicated to VTRS by these funds increased significantly by 22.74% to 0.18%. Examining individual large shareholders, Price T Rowe Associates boosted its VTRS holdings by 21.19% to 74,461K shares (6.34% ownership) and Davis Selected Advisers increased its position by 3.66% to 64,948K shares (5.53% ownership). In contrast, Pacer US Cash Cows 100 ETF reduced its stake by 12.31%. Notably, several major holders, including Price T Rowe, Davis Selected Advisers, Vanguard Total Stock Market Index Fund, and Vanguard 500 Index Fund, despite increasing their absolute share counts in Viatris, concurrently reduced their portfolio allocation to the stock (by 5.12%, 27.98%, 26.40%, and 26.60% respectively), indicating these share increases might not reflect heightened conviction but rather broader rebalancing or relative value considerations within their portfolios.

Key Decisions for Investors

• Investors should consider the dichotomy between Goldman Sachs' Neutral rating and the significant 28.60% upside indicated by the consensus analyst price target, suggesting potential undervaluation but also underlying risks or uncertainties recognized by the initiating analyst.
• The conflicting institutional signals—decreasing fund participation and total shares alongside a rising average portfolio weight and selective buying by some large funds—necessitate close observation of subsequent institutional ownership trends to gauge emerging consensus.
• Given the projected revenue and EPS growth contrasted with the reduced portfolio allocations by key institutions, investors should closely monitor Viatris's upcoming financial performance and management guidance for fundamental validation of the growth outlook and to assess if the stock can overcome the observed institutional caution.